Tributyrin
In clinical developmentAlso known as Glycerol Tributyrate.
Recent clinical, regulatory, research and industry developments relating to this drug.
Investigational Study of Glycerol Tributyrate in MELAS and LHON-Plus
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
PHASE I STUDY OF THE ORALLY ADMINISTERED BUTYRATE PRODRUG, TRIBUTYRIN, IN PATIENTS WITH SOLID TUMORS
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- European journal of pharmacology1
- Del Olmo N1
- Roca M1
- Ruiz-Gayo M1
- Sanz-Martos AB1
- School of Pharmacy1
- School of Psychology1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials